Journal: Oncology Letters

Article Title: Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo

doi: 10.3892/ol.2017.6602

Figure Lengend Snippet: Effects of CDHP and/or CDDP on tumor growth inhibition in vivo . (A) Control, CDHP and CDDP treatment protocol. There were four experimental groups of mice: Control group, administered orally 0.5% HPMC (200 µl, 7 times/week) and saline (200 µl, once/week) by IP for 2 weeks; CDHP group, administered CDHP (2.0 mg/kg, PO, 7 times/week) and saline (200 µl IP, once/week) for 2 weeks; CDDP group, administered 0.5% HPMC (200 µl, PO, 7 times/week) and with CDDP (6.0 mg/kg/day, IP, once/week) for 2 weeks; and CDDP+CDHP combination therapy group, which received CDHP (2.0 mg/kg, PO, 7 times/week) and CDDP (6.0 mg/kg/day, IP, once/week) for 2 weeks. (B) CDHP+CDDP treatment significantly inhibited SAS and HSC2 tumor growth compared with that of CDDP treatment alone. CDHP or HPMC alone did not inhibit tumor growth. (C) CDHP and/or CDDP did not cause significant weight loss in any of the treatment groups compared with that of the untreated control. Error bars represent the standard error of the mean from the results of 5 mice (n=5). *P<0.01 compared with the control (Mann-Whitney's U test). # P<0.01 compared with CDDP alone (Mann-Whitney's U test). CDHP, 5-chloro-2,4-dihydroxypyridine; CDDP, cisplatin; HPMC, hydroxypropylmethylcellulose; PO, per os; IP, intraperitoneal injection.

Article Snippet: CDHP was suspended in sterile 0.5% sodium hydroxypropylmethylcellulose (HPMC; DKS Co., Ltd., Kyoto, Japan) in sterile conditions at 1.0 mg/ml and subsequently homogenized.

Techniques: Inhibition, In Vivo, Control, Saline, MANN-WHITNEY, Injection